ESMO 2014 - Prostate Cancer

COU-AA-302 Final Update: Abiraterone Acetate Maintains Overall Survival Advantage in Chemotherapy-Naïve Patients with Metastatic Prostate Cancer

Conference Correspondent - ESMO 2014 - Prostate Cancer

Abiraterone acetate is a prodrug of abiraterone, a selective CYP17 inhibitor that blocks androgen synthesis, and is approved, together with prednisone, for the treatment of progressive metastatic castrate-resistant prostate cancer (mCRPC). The COU-AA-302 study was a randomized, phase 3 clinical [ Read More ]

SYNERGY: Adding Custirsen to Docetaxel plus Prednisone Regimen Does Not Improve Outcomes in Patients with Metastatic Prostate Cancer

Conference Correspondent - ESMO 2014 - Prostate Cancer

Custirsen is a second-generation antisense oligonucleotide that inhibits production of human clusterin, a prosurvival chaperone protein upregulated in tumor cells in response to apoptotic stressors such as chemotherapy. Chi and colleagues reported the results from the SYNERGY study, a randomized [ Read More ]

Subanalysis of TROPIC Trial: Cabazitaxel plus Prednisone versus Mitoxantrone after Docetaxel in Patients with Different Prognostic Risk Factors

Conference Correspondent - ESMO 2014 - Prostate Cancer

Previous results of the TROPIC trial showed that patients with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with cabazitaxel plus prednisone (CP) had improved overall survival (OS) compared with patients who received mitoxantrone plus prednisone (MP; Bahl A, et [ Read More ]